FINWIRES · TerminalLIVE
FINWIRES

研究快讯:CMG:交易增长回归;利润率承压

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:CMG第一季度每股收益为0.24美元,同比下降17%,但与市场预期一致;营收为30.9亿美元(同比增长7.4%),高于市场预期的30.6亿美元。同店销售额增长0.5%,高于预期的0.8%的降幅,主要得益于交易量增长0.6%。我们认为,保持稳定的交易量增长比承受短期利润率压力更为重要,因为这表明尽管受到关税影响,CMG仍然是消费者的一个有价值选择。管理层维持业绩指引不变,预计2026年同店销售额将保持平稳增长,并计划开设350-370家新店。由于人工成本(增长10.5%)和食品成本(增长8.6%)上升,餐厅层面的利润率下降了250个基点,这反映了为了吸引客流而限制价格所带来的权衡。数字渠道占比提升至 38.6%,CMG 新开了 49 家门店。公司回购了价值 7.008 亿美元的股票,同时创造了 4.71 亿美元的健康自由现金流(增长 14%)。鉴于宏观经济波动,我们认为 CMG 的策略较为保守。随着一系列会员忠诚度计划的推进,我们认为交易量有望实现环比增长。

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ